Your browser is no longer supported. Please, upgrade your browser.
Idera Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.75 Insider Own0.40% Shs Outstand52.74M Perf Week3.51%
Market Cap37.72M Forward P/E- EPS next Y-0.44 Insider Trans4.62% Shs Float41.28M Perf Month9.15%
Income25.50M PEG- EPS next Q-0.11 Inst Own11.80% Short Float0.67% Perf Quarter-27.30%
Sales- P/S- EPS this Y-12.50% Inst Trans-0.04% Short Ratio0.25 Perf Half Y-34.63%
Book/sh0.63 P/B1.06 EPS next Y-123.90% ROA58.60% Target Price- Perf Year-87.65%
Cash/sh- P/C- EPS next 5Y- ROE466.60% 52W Range0.51 - 6.14 Perf YTD16.98%
Dividend- P/FCF- EPS past 5Y0.30% ROI- 52W High-89.14% Beta1.50
Dividend %- Quick Ratio6.90 Sales past 5Y- Gross Margin- 52W Low31.39% ATR0.07
Employees32 Current Ratio6.90 Sales Q/Q- Oper. Margin- RSI (14)51.75 Volatility10.33% 8.18%
OptionableYes Debt/Eq0.00 EPS Q/Q80.70% Profit Margin- Rel Volume1.98 Prev Close0.65
ShortableYes LT Debt/Eq0.00 EarningsNov 08 AMC Payout0.00% Avg Volume1.10M Price0.67
Recom3.00 SMA208.98% SMA50-3.59% SMA200-32.75% Volume2,167,786 Change1.94%
Mar-19-21Downgrade Wedbush Outperform → Neutral $8 → $1
Mar-19-21Downgrade JP Morgan Overweight → Neutral
Mar-19-21Downgrade JMP Securities Mkt Outperform → Mkt Perform
Mar-19-21Downgrade H.C. Wainwright Buy → Neutral
Mar-19-21Downgrade Barclays Overweight → Equal Weight $10 → $2
Sep-24-18Initiated Barclays Overweight $14
Aug-15-18Resumed JP Morgan Overweight $15
Nov-09-17Initiated H.C. Wainwright Buy $4
Apr-25-17Initiated Robert W. Baird Outperform $5
Mar-22-17Initiated JMP Securities Mkt Outperform
Feb-01-17Reiterated Wedbush Outperform $6
Jan-06-16Initiated Wedbush Outperform $6
Jun-15-15Initiated JP Morgan Overweight
Mar-03-14Initiated Cowen Outperform
Mar-24-10Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $10
Nov-21-08Initiated Noble Financial Buy
Oct-27-08Upgrade Susquehanna Financial Negative → Neutral
Aug-06-08Downgrade Canaccord Adams Buy → Hold
May-07-08Downgrade Janney Mntgmy Scott Buy → Neutral
May-02-08Downgrade Susquehanna Financial Neutral → Negative $11
Dec-14-21 04:32PM  
Nov-08-21 04:14PM  
Aug-09-21 04:15PM  
Jun-05-21 05:59AM  
May-19-21 07:56AM  
May-18-21 04:15PM  
Apr-29-21 04:10PM  
Mar-19-21 12:04PM  
Mar-18-21 04:15PM  
Mar-07-21 03:31AM  
Mar-01-21 04:35PM  
Feb-28-21 02:49AM  
Feb-26-21 06:50AM  
Jan-11-21 06:02AM  
Dec-18-20 02:22AM  
Dec-17-20 08:45AM  
Dec-15-20 08:05AM  
Dec-04-20 08:34AM  
Nov-17-20 04:27PM  
Nov-03-20 07:10AM  
Oct-29-20 04:36PM  
Sep-28-20 08:45AM  
Sep-15-20 07:18AM  
Sep-10-20 10:13AM  
Aug-04-20 04:10PM  
Jul-15-20 08:05AM  
Jun-21-20 11:13PM  
Jun-02-20 08:15AM  
May-01-20 08:00AM  
Apr-30-20 04:35PM  
Apr-23-20 07:30AM  
Apr-21-20 07:30AM  
Apr-10-20 01:49PM  
Apr-07-20 04:05PM  
Mar-12-20 07:30AM  
Mar-06-20 11:14AM  
Mar-05-20 07:00AM  
Jan-14-20 07:00AM  
Dec-24-19 12:05PM  
Dec-23-19 09:15AM  
Dec-16-19 04:39PM  
Nov-19-19 09:40AM  
Nov-06-19 04:01PM  
Nov-01-19 10:03AM  
Oct-25-19 10:46AM  
Oct-21-19 07:00AM  
Sep-30-19 07:30AM  
Sep-10-19 09:33AM  
Sep-04-19 07:00AM  
Aug-30-19 12:00PM  
Aug-17-19 04:20AM  
Aug-08-19 10:15AM  
Aug-06-19 04:00PM  
Jul-25-19 10:33AM  
Jul-23-19 07:30AM  
Jul-10-19 01:46PM  
Jun-18-19 04:00PM  
May-10-19 09:35AM  
May-02-19 08:55PM  
May-01-19 10:32AM  
Apr-29-19 08:34AM  
Apr-10-19 07:00AM  
Apr-02-19 07:00AM  
Mar-14-19 11:21AM  
Mar-07-19 01:55PM  
Mar-06-19 04:30PM  
Feb-27-19 07:00AM  
Jan-23-19 12:55PM  
Jan-18-19 01:08PM  
Jan-04-19 07:30AM  
Dec-18-18 04:05PM  
Dec-17-18 07:00AM  
Dec-14-18 07:00AM  
Dec-12-18 04:01PM  
Dec-11-18 07:20AM  
Dec-08-18 10:02AM  
Nov-27-18 01:01PM  
Nov-06-18 06:35PM  
Oct-19-18 06:00AM  
Oct-15-18 07:55AM  
Oct-11-18 08:34AM  
Sep-25-18 03:47PM  
Sep-18-18 04:01PM  
Sep-11-18 07:00AM  
Aug-30-18 07:30AM  
Aug-18-18 08:32AM  
Aug-14-18 07:35AM  
Aug-12-18 11:46AM  
Aug-10-18 08:00AM  
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kirby John J.CHIEF FINANCIAL OFFICERDec 17Buy0.6110,0006,15037,632Dec 21 04:16 PM
SOLAND DANIEL BCHIEF OPERATING OFFICERJun 18Buy1.1950,00059,50078,843Jun 21 04:10 PM
DOUGHERTY MICHAEL RDirectorJun 01Buy1.1985,000101,150133,584Jun 03 04:10 PM
Tarka Elizabeth AnnCHIEF MEDICAL OFFICERMar 25Sale1.355,0186,77813,237Mar 29 04:14 PM
Lim Bryant DavidSVP AND GENERAL COUNSELMar 25Sale1.367,63010,37830,434Mar 29 04:09 PM
Kirby John J.CHIEF FINANCIAL OFFICERMar 25Sale1.426,2508,87627,632Mar 29 04:05 PM
SOLAND DANIEL BCHIEF OPERATING OFFICERMar 05Buy3.9010,00038,95028,843Mar 05 05:55 PM